CDC advisory panel says U.S. should resume Johnson & Johnson vaccine
Resuming the vaccine is "in the best public health interest" of the country, panel member claims.
The Facts Inside Our Reporter’s Notebook
The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices said on Friday that the United States should resume dispensing the Johnson & Johnson COVID-19 vaccine, a little over a week after federal health authorities recommended a pause in the vaccine due to concerns over potential blood clots.
CDC Director Rochelle Walensky will decide whether or not to accept the panel's recommendation. Walensky herself said on Friday that she anticipates that she'll make the decision "quickly."
The panel voted 10-4, with one abstention, in favor of resuming the shots, though it advised that a warning about the blood clots should accompany the administration of the vaccine.
About 40% of the U.S. has received at least one dose of a COVID-19 vaccine as of this week.
News, not Noise
- Parents of alleged Michigan high school shooter return for arraignment, not on the run, attorneys
- Early lids, lighter duty: Biden schedule marked by fewer events, more getaways than predecessors
- 'Laptop from Hell' author: Biden lied about not knowing of 'Hunter's overseas business dealings'
- Too good to fact-check? Academic journal publishes hoax on conservative takeover of higher ed
- Outrageous tab: Minnesota school charges $901,000 for critical race theory records